Henry James International Management Inc. Adaptimmune Therapeutics PLC Transaction History

Henry James International Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$1.73 - $4.06 $74,511 - $174,864	-43,070 Closed	0 $0
Q2 2021 Jul 30, 2021	SELL	$3.86 - $5.78 $165,980 - $248,540	-43,000 Reduced 49.96%	43,070 $183,000
Q1 2021 Apr 19, 2021	BUY	$4.9 - $6.83 $421,743 - $587,858	86,070 New	86,070 $457,000
Q1 2019 Apr 22, 2019	SELL	$3.63 - $6.06 $90,848 - $151,663	-25,027 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$3.76 - $14.16 $94,101 - $354,382	25,027 New	25,027 $144,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Henry James International Management Inc., based on Form 13F filings with the SEC.

Stay updated on Henry James International Management Inc. with notifications on news.